Cystic Fibrosis (CF) is an autosomal recessive disease that is the result of defective CF transmembrane conductance regulator (CFTR) ion transport function at the cell surface membrane. Individuals suffering this fate can expect to live to their late-thirties. A frequent mutation affecting most CF patients is the F508del mutation found in at least one CF allele at > 80% frequency. This mutant F508del CFTR is a misfolded form of CFTR that is impaired in its ability to traffic to the cytoplasmic apical membrane where it primarily functions as a cAMP-dependent Cl channel, albeit with lowered efficiency. A long non-coding RNA (lncRNA) has been identified that is involved in transcriptional regulation of CFTR. Preliminary studies indicate that inhibition of this lncRNA can result in increased expression of mutant CFTR at the cell surface. Therefore, the studies proposed here will test the hypothesis that sustainable expression of mutant CFTR can be achieved in human cells such that there is physiologically and therapeutically efficacious CFTR-associated cAMP-dependent Cl ion transport function present at the apical membrane of epithelial cells. We have developed three aims to test our hypothesis.
In aim 1, we will develop and contrast vector and oligonucleotide targeted activation of CFTR, in aim 2, we will characterize the functional components involved in lncRNA modulation of CFTR and in aim 3 we will determine the genome targeting and gene expression profile of these lncRNAs BG213071 and AI805947 in expressing and repressed cells. These studies represent the development of a new therapeutic paradigm for CF, i.e., targeting lncRNAs to affect the function of the protein-coding gene targets that they regulate. In this context, several novel approaches targeted to CFTR-associated lncRNAs will be developed and tested to enhance CFTR expression and function. This new pathway for regulation of CFTR expression by lncRNA could lead to significant insights into those cellular pathways involved in the modulation of CFTR expression during development and in response to secondary infections as well as to the development of a new class of therapeutic agents to treat CF.
This project will develop and mechanistically characterize a new pathway for activating CFTR expression by the targeted disruption of endogenous CFTR regulatory long non-coding RNAs. Such a methodology has the potential to result in long-term stable activation of CFTR in Cystic Fibrosis patients containing the common F508del mutation and ultimately the development of a new class of therapeutic targets for treating Cystic Fibrosis.
| Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590 |
| Shevchenko, Galina; Morris, Kevin V (2018) All I's on the RADAR: role of ADAR in gene regulation. FEBS Lett 592:2860-2873 |
| Jia, Jieshuang; Werkmeister, Elisabeth; Gonzalez-Hilarion, Sara et al. (2017) Premature termination codon readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins. J Cell Sci 130:3009-3022 |
| Lister, Nicholas; Shevchenko, Galina; Walshe, James L et al. (2017) The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene. Proc Natl Acad Sci U S A 114:9942-9947 |
| Weinberg, Marc S; Morris, Kevin V (2016) Transcriptional gene silencing in humans. Nucleic Acids Res 44:6505-17 |
| Saayman, Sheena M; Ackley, Amanda; Burdach, Jon et al. (2016) Long Non-coding RNA BGas Regulates the Cystic Fibrosis Transmembrane Conductance Regulator. Mol Ther 24:1351-7 |
| Fortes, Puri; Morris, Kevin V (2016) Long noncoding RNAs in viral infections. Virus Res 212:1-11 |
| Hewson, Chris; Morris, Kevin V (2016) Form and Function of Exosome-Associated Long Non-coding RNAs in Cancer. Curr Top Microbiol Immunol 394:41-56 |
| Lazar, Daniel C; Morris, Kevin V; Saayman, Sheena M (2016) The emerging role of long non-coding RNAs in HIV infection. Virus Res 212:114-26 |
| Saayman, Sheena M; Lazar, Daniel C; Scott, Tristan A et al. (2016) Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Mol Ther 24:488-98 |
